A2AR antagonists are now approved as a new therapeutic tool to manage PD [16] and we recently defined that targeting CD73 was equieffective to A2AR antagonists to alleviate motor symptoms in an animal model of PD [9]. This evidence concerns the gene NT5E and Parkinson disease.